A Review of Clinical Studies of Bestatin

  • S. Oka
Chapter
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 75)

Abstract

Bestatin has no clinical toxicity. It increases the number of T cells and enhances NK cell activity. The optimal dose of bestatin was thought to range from 30–100 mg/day/body, and 200 mg/day/body often decreased T-cell number.

The clinical effects were as follows:
  1. 1)

    Bestatin alone: possible cure in one case of residual penile tumor after bleomycin treatment; marked regression in two cases of skin metastasis of mammary carcinoma.

     
  2. 2)

    Radiation and bestatin: complete regression in three cases of Virchow’s nodes.

     
  3. 3)

    Pepleomycin and bestatin: complete regression in one case of metastatic skin adenocarcinoma.

     
  4. 4)

    Possible favorable effect of bestatin against esophageal carcinoma in combination with radiation and bleomycin.

     

Keywords

Penile Cancer Anterior Chest Wall Cooperative Study Group Cancer Patient Treat Bleomycin Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Aoike A, Tanaka Y, Hosokawa T, Yamaguchi N, Kawai K (to be published) Effect of bestatin on natural killer activity. In: Small molecular immunomodulators of microbial origin. Japan Scientific Societies Press, TokyoGoogle Scholar
  2. 2.
    Aoyagi T, Suda H, Nagai M, Ogawa K, Suzuki J, Takeuchi T, Umezawa H (1976) Aminopeptidase activities on the surface of mammalian cells. Biochim Biophys Acta 452:131–143PubMedGoogle Scholar
  3. 3.
    Cooperative Study Group on Bestatin (1979) In: Interim report, part 1, Cooperative Study Group on Bestatin, Tokyo, pp 1–120, 1979; part 2, Cooperative Study Group on Bestatin, Tokyo, pp 1–93Google Scholar
  4. 4.
    Ichikawa T, Isurugi K (1978) Effect of a new immunomodulator, bestatin, in the treatment of urogenital malignancies. Read before the 12th International Congress of Cancer, Buenos Aires, OctoberGoogle Scholar
  5. 5.
    Kondo T, Watanabe N, Tachibana T (1978) Rapid and simple assay in microtest plate for enumeration of human T and B lymphocyte populations. Strides Med 107:312–314Google Scholar
  6. 6.
    Tachibana T, Yoshida A (1974) Determination of human T and B lymphocyte populations in microtest plate (an improved method). In: The Japanese Society for Immunology (eds) Experimental methods in immunology A (in Japanese), pp 907–914Google Scholar
  7. 7.
    Umezawa H (1977) Recent advances in bioactive microbial secondary metabolites. Jpn J Antibiot 30 [Suppl]: 138–163PubMedGoogle Scholar
  8. 8.
    Umezawa H, Aoyagi T, Suda H, Hamada M, Takeuchi T (1976) Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes. J Antibiot (Tokyo) 29:97–99Google Scholar
  9. 9.
    Umezawa H, Ishizuka M, Aoyagi T, Takeuchi T (1976) Enhancement of delayed-type hypersensitivity by bestatin, an inhibitor of aminopeptidase B and leucine aminopeptidase. J Antibiot (Tokyo) 29:857–859Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1980

Authors and Affiliations

  • S. Oka

There are no affiliations available

Personalised recommendations